Brind.
  1. Abeona Therapeutics received FDA approval, enabling commercial launch and securing an NDRA agreement for expedited coverage from CMS.

Abeona Therapeutics' therapy launch is being supported by a HUB partnership and patient-centric solutions.

1 report, 1 independent Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Abeona Therapeutics' therapy launch is being supported by a HUB partnership and patient-centric solutions.

Who's involved

What this event is mainly about
Abeona Therapeutics

How it developed

Newest first. Tap a step to see who reported it.
  1. Abeona Therapeutics collaborates with the University of Texas Medical Branch on clinical trials and patient care.Sub-event
  2. Abeona Therapeutics commercialized ZEVASKYN therapy and partnered with Stanford Medicine and Lucile Packard Children’s Hospital to treat RDEB patients.Sub-event
  3. A HUB partnership and patient-centric solutions are supporting the commercial launch of Abeona's therapy.1 source

Keep exploring

Part of

Abeona Therapeutics received FDA approval, enabling commercial launch and securing an NDRA agreement for expedited coverage from CMS. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients BERWYN, Pa., July 29, 2025 (GLOBE NE